ADXS - Advaxis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.4021
-0.0179 (-4.26%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.4200
Open0.4400
Bid0.4023 x 1000
Ask0.4299 x 1100
Day's Range0.4000 - 0.4400
52 Week Range0.3550 - 23.7000
Volume457,378
Avg. Volume520,481
Market Cap7.508M
Beta (3Y Monthly)3.80
PE Ratio (TTM)N/A
EPS (TTM)-6.9980
Earnings DateSep 9, 2019 - Sep 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.65
Trade prices are not sourced from all markets
  • Business Wire

    Advaxis, Inc. Issues Letter to Shareholders

    Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that its chief executive officer, Kenneth A. Berlin, issued an open letter to Advaxis’ stockholders. The following letter can also be viewed on the Investor Relations section of the Advaxis website. Innovation, particularly in a highly regulated industry such as drug development, often results in ebbs and flows of successes and failures accompanied by investor optimism and skepticism.

  • GlobeNewswire

    BriaCell Appoints Richard J. Berman to Board of Directors

    BERKELEY, Calif., and VANCOUVER, British Columbia, Aug. 12, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.

  • Business Wire

    Advaxis, Inc. Announces Closing of $17 Million Public Offering and Exercise in Full of the Underwriters' Over-Allotment Option

    Advaxis, Inc. (ADXS) (the “Company”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the closing of its previously announced underwritten public offering of (i) 10,650,000 shares of common stock together with common stock warrants (the “common warrants”) to purchase 7,987,500 shares of common stock and (ii) 13,656,000 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock, together with common warrants to purchase 10,242,000 shares of common stock, which included the exercise in full of the over-allotment option to purchase additional shares of common stock and warrants.

  • Benzinga

    The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 23) Akero Therapeutics Inc (NASDAQ: AKRO ) Mirum Pharmaceuticals ...

  • Business Wire

    Advaxis, Inc. Announces Pricing of $16 Million Public Offering

    Advaxis, Inc. (ADXS) (the “Company”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of (i) 9,200,000 shares of common stock together with common stock warrants (the “common warrants”) to purchase 6,900,000 shares of common stock and (ii) 13,656,000 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock, together with common warrants to purchase 10,242,000 shares of common stock. The shares of common stock (or pre-funded warrants, as applicable) and accompanying common warrants are being sold together at a combined public offering price of $0.70 per share.

  • Business Wire

    New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed Immunotherapies

    Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced new immune data from its ongoing ADXS-NEO Phase 1 clinical trial that further support the clinical potential for the company’s platform in neoantigen-directed immunotherapies. ADXS-NEO is a personalized immunotherapy that is designed to help a patient’s immune system recognize and respond to mutation-derived tumor antigens, or neoantigens, that are unique to his or her tumor. ADXS-NEO is designed to express tLLO fused to up to 40 patient-specific neoantigens arranged sequentially as beads-on-a-string.

  • Business Wire

    Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of Its Phase 3 AIM2CERV Study

    Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it is increasing its focus on neoantigen-directed immunotherapies and closing the AIM2CERV Phase 3 clinical trial with axalimogene filolisbac (AXAL) in high-risk locally advanced cervical cancer. Advaxis intends to continue to support the clinical development of AXAL, its single-antigen construct, in other HPV-related cancers while redirecting resources towards advancing its neoantigen-directed programs.

  • Thomson Reuters StreetEvents

    Edited Transcript of ADXS earnings conference call or presentation 11-Jun-19 3:00pm GMT

    Q2 2019 Advaxis Inc Earnings Call

  • ACCESSWIRE

    Advaxis, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / June 11, 2019 / Advaxis, Inc. (NASDAQ: ADXS ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on June 11, 2019 at 11:00 AM Eastern ...

  • Business Wire

    Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update

    Conference call to be held June 11 at 11:00 a.m. ET

  • Business Wire

    Advaxis to Host Business Update Conference Call on June 11, 2019

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the company will host a business update call on Tuesday, June 11, 2019 at 11:00 a.m. ET. During the call, Advaxis’ senior management will review the company’s clinical development programs and recent financial results, and provide a general business update. The company intends to issue a news release summarizing financial results for the fiscal second quarter ended April 30, 2019 after market close on Monday, June 10, 2019.

  • What Kind Of Investor Owns Most Of Advaxis, Inc. (NASDAQ:ADXS)?
    Simply Wall St.

    What Kind Of Investor Owns Most Of Advaxis, Inc. (NASDAQ:ADXS)?

    The big shareholder groups in Advaxis, Inc. (NASDAQ:ADXS) have power over the company. Large companies usually have...

  • Benzinga

    Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug

    Nanocap Advaxis, Inc. (NASDAQ: ADXS ) is seeing strength Wednesday following an announcement concerning its cervical cancer drug. What Happened Advaxis announced the lifting of a partial clinical hold ...

  • Business Wire

    FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA or Agency) has lifted the partial clinical hold on AIM2CERV, the company’s Phase 3 clinical trial of axalimogene filolisbac (AXAL) for the treatment of patients with high-risk locally advanced cervical cancer. In its letter, the FDA acknowledged that the company satisfactorily addressed all hold questions. As announced on January 23, 2019, the FDA placed a partial clinical hold on this study relating to the Agency’s requests for additional information pertaining to certain AXAL chemistry, manufacturing and controls (CMC) matters. The Agency did not cite any safety issues related to the trial and all enrolled patients continued to receive treatment, per the trial protocol.

  • Business Wire

    Advaxis Announces Two Poster Presentations at the Frontiers in Cancer Immunotherapy Conference

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of two posters at the Frontiers in Cancer Immunotherapy conference, being held today at the New York Academy of Sciences in New York City. Both posters were first presented at the recent American Association for Cancer Research (AACR) Annual Meeting, and each has updated findings being presented today. The first presentation regarding a poster entitled “Effects of ADXS-PSA With or Without Pembrolizumab on Survival and Antigen Spreading in Metastatic, Castration-Resistant Prostate Cancer Patients (Results from KEYNOTE-046)” is conference poster #31, and will be presented by Robert Petit, Ph.D., Advaxis Chief Scientific Officer, and Mark N. Stein, M.D., FACS, Associate Professor of Medical Oncology at Columbia University Medical Center, from 4:45 to 5:30 p.m. Eastern time.

  • Business Wire

    Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer

    Advaxis, Inc. (ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Robert Petit, Ph.D. will be leaving his position as Chief Scientific Officer at the end of the month. Dr. Petit will assist the Company in transitioning his duties over the next several weeks, and will continue to support the Company as an advisor and consultant in his capacity as the new Chair of the Advaxis Scientific Advisory Board, effective June 3, 2019.

  • Business Wire

    Advaxis to Participate in Five Upcoming Industry Conferences

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces participation in f

  • Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know
    Zacks

    Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know

    Advaxis (ADXS) closed the most recent trading day at $3.29, moving -0.3% from the previous trading session.

  • QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
    Zacks

    QIAGEN Drives Molecular Diagnostics Suite With New Test Kit

    QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.

  • Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session
    Zacks

    Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session

    Twist Bioscience (TWST) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year?

    Is (ADXS) Outperforming Other Medical Stocks This Year?

  • Why Range Resources, Advaxis, and StoneCo Slumped Today
    Motley Fool

    Why Range Resources, Advaxis, and StoneCo Slumped Today

    Equity offerings played a big role for two of these companies.

  • Benzinga

    The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...

  • Business Wire

    Advaxis Announces Pricing of Its Public Offering of Common Stock

    Advaxis, Inc. (ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $4.00 per share. The gross proceeds to Advaxis, Inc. from this offering are expected to be approximately $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses.